Exhibit 99.1

Sucampo Pharmaceuticals, Inc. Reports Third Quarter 2011 and Year to Date Financial Results

Conference Call Today at 5:00 pm Eastern

BETHESDA, Md.--(BUSINESS WIRE)--November 3, 2011--Sucampo Pharmaceuticals, Inc. (“Sucampo”), (NASDAQ: SCMP) (SPI), an international pharmaceutical company, today reported its consolidated financial results for the quarter and year-to-date ended September 30, 2011.

Sucampo reported a net loss of $4.1 million, or $0.10 per diluted share, for the third quarter compared to a net income of $1.9 million, or $0.05 per diluted share, for the same period in 2010. Sucampo reported a net loss of $20.0 million, or $0.48 per diluted share, for first nine months of 2011, compared to net income of $3.6 million, or $0.09 per diluted share, for the first nine months of 2010.

“As I have stated many times, we are committed to bringing novel medicines to patients with significant unmet medical needs on a global basis as well as vigorously protecting the value of our approved products. We are delighted that we are seeing some of the results of our labors. We successfully settled the dispute with Covance Inc. that managed our earlier phase 3 trials of lubiprostone for opioid-induced bowel dysfunction, or OBD. We now look forward to the results of our third phase 3 trial of lubiprostone for OBD by the year end. We also are on schedule to resolve our dispute with Takeda with the arbitration hearings currently set for December and a final decision thereafter,” said Ryuji Ueno, M.D., Ph.D., Ph.D., Chairman and Chief Executive Officer.

Dr. Ueno continued, “There are other visible results of our efforts. We made significant talent additions to Sucampo, by adding Dr. Daniel P. Getman to our Board of Directors, Mr. Cary J. Claiborne as CFO, Dr. Peter Lichtlen to our R&D team, and Mr. Greg Deener to our commercial organization. Their significant and varied expertise and insights strengthen our Board and senior management team considerably as we continue to grow the business.”

Financial Results for the Quarter and Year-to-Date

As previously reported, Sucampo Pharmaceuticals, Inc. acquired Sucampo AG (SAG) and its subsidiary Sucampo AG Japan (SAG-J) in December 2010. This transaction has been accounted for as a merger of companies under common control and at historical costs. The financial information for these entities is consolidated and presented in both the current and historical periods. Additional information on the effect of including SAG and its subsidiary has been highlighted within the commentary.

For the third quarter of 2011, Sucampo reported total revenue of $14.4 million, compared to $20.9 million for the same period in 2010. The key components of total revenue in the third quarter of 2011 included product royalty revenue of $10.6 million and R&D revenue of $2.9 million, which compare to $10.4 million and $9.1 million, respectively, in the same period of 2010. For the first nine months of 2011, Sucampo reported total revenue of $40.5 million, compared to $49.5 million for the same period in 2010. The key components of total revenue for the nine month period were product royalty revenue of $30.7 million and R&D revenue of $6.6 million, compared to $29.8 million and $15.9 million, respectively, in the same period of 2010. The increase in product royalty revenue was due to an increase in net sales as reported by Takeda Pharmaceuticals North America, Inc (Takeda) with which we have a collaboration agreement covering the United States and Canada. The decrease in R&D revenue was primarily due to completion of our Japanese clinical development program for lubiprostone under our agreement with Abbott Japan Co., Ltd., as we await the review of our new drug application, or NDA, by the Japanese Ministry of Health, Labour and Welfare that we filed in September, 2010.

Net sales of AMITIZA^® (lubiprostone) as reported to us by Takeda, increased 1.1%, to $57.6 million, for the third quarter 2011, from the $57.0 million recorded in the same period in 2010. AMITIZA’s Total Prescriptions (TRx), as reported by IMS, grew by 8,400 TRx during the third quarter 2011. Net sales of AMITIZA as reported to us by Takeda for the nine months ended September 30, 2011, increased 3.0% to $169.6 million from the $164.7 million recorded in the same period in 2010. AMITIZA’s TRx growth, as reported by IMS, for the first nine months of 2011 increased 4.5% over the prior nine months and increased 6.3% over the same period last year.

Operating Expenses

R&D expenses were $8.7 million in the third quarter of 2011, compared to $6.3 million for the same period in 2010. For the first nine months of 2011, R&D expenses were $25.8 million, compared to $16.5 million for the same period of 2010. For both periods, the increase was primarily due to expenses associated with the ongoing third phase 3 clinical trial of lubiprostone for OBD and re-monitoring costs for previous trials which were the subject of the litigation with Covance Inc. We receive reimbursement from Takeda under our collaboration agreement for 50% of the expenses for the third phase 3 trial and the re-monitoring costs.

G&A expenses were $7.9 million in the third quarter of 2011, compared to $6.4 million for the same period last year. G&A expenses were $29.3 million for the nine months ended September 30, 2011, compared to $19.0 million for the nine months ended September 30, 2010, an increase of $10.3 million or 54%. For both periods, the increase in G&A expenses includes costs incurred from on-going legal, consulting and other professional expense relating primarily to on-going legal matters, including our dispute with Takeda, a separate dispute with Covance that has now been settled and consolidation of subsidiaries and SAG integration.

Selling and marketing expenses were $2.2 million for the third quarter of 2011, compared to $2.6 million for the same period last year. Selling and marketing expenses were $6.7 million for the nine months ended September 30, 2011, compared to $7.1 million for the nine months ended September 30, 2010, a decrease of $0.4 million or 6% primarily related to a reduction of expenses in Europe.

Non-Operating Income (Expense)

Non-operating income was $0.6 million in the third quarter of 2011, compared to non-operating expenses of $3.3 million for the same period in 2010. Non-operating expenses were $3.7 million for the nine months ended September 30, 2011, compared to non-operating expenses of $2.1 million for the same period in 2010. Non-operating expenses for the third quarter of 2011 included $0.6 million in loan note interest that is related to the SAG acquisition, compared to none for the same period last year. Non-operating expenses for the nine months ended September 30, 2011, included $1.8 million in loan note interest of which $1.7 million was related to the SAG acquisition, compared to none for the same period last year. The third quarter of 2011 includes a foreign exchange gain of $1.2 million compared to a loss of $3.4 million for the same period last year. The nine months ended September 30, 2011, includes a foreign exchange loss of $2.0 million compared to a loss of $2.6 million for the same period last year.

Net Income (Loss)

Net loss for the third quarter 2011 was $4.1 million, compared to net income of $1.9 million for the same period in 2010, which included a $0.5 million loss from SAG now incorporated in the results. Net loss for the first nine months of 2011 was $20.0 million, compared to net income of $3.6 million for the same period in 2010, which included $3.4 million income from SAG now incorporated in the results.

Comprehensive Income (Loss)

Comprehensive loss for the third quarter 2011 was $6.1 million, compared to comprehensive income of $6.1 million for the same period in 2010, which included $3.3 million income from SAG now incorporated in the results. Comprehensive loss for the third quarter 2011 includes $2.1 million foreign currency translation loss compared to a gain of $4.2 million in the same period last year.

Comprehensive loss for the first nine months of 2011 was $18.7 million, compared to comprehensive income of $6.1 million for the same period in 2010, which included $5.7 million income from SAG now incorporated in the results. Comprehensive loss for the first nine months of 2011 includes $1.2 million foreign currency translation gain compared to a gain of $2.5 million in the same period last year.

Cash, Cash Equivalents, Restricted Cash and Marketable Securities

At September 30, 2011, cash, cash equivalents, restricted cash and investments were $104.6 million, compared to $123.9 million at December 31, 2010. At September 30, 2011, notes payable were $66.7 million, compared to $64.0 million at December 31, 2010, including current notes payable of $20.5 million at September 30, 2011, and $19.5 million at December 31, 2010.

In September 2011, the Board of Directors approved the repurchase of our Class A common stock under the previously approved repurchase plan, up to an aggregate of $2.0 million. As of the end of the quarter, we had repurchased 42,274 shares at an aggregate purchase price of $149,060.

Operational Highlights

• After the end of the 2011 third quarter, we settled a lawsuit against Covance Inc. regarding its performance of the OBD phase 3 clinical trials. As part of the settlement agreement, they agreed to pay us $10.0 million and cancel $1.1 million in outstanding invoices owed.
• As previously reported, we completed the enrollment of 447 patients into our third phase 3 clinical trial of lubiprostone in non-cancer pain patients with OBD excluding those patients taking methadone. The primary endpoint of this trial is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs). We expect to report top-line results of this trial in mid to late December 2011. If successful, the results of this trial will be used to support a regulatory filing in the U.S. and Europe during the first half of 2012.
• We continued to work on reaching a conclusion in the arbitration with Takeda at the International Court of Arbitration, International Chamber of Commerce. The opening submission and witness statements have been filed by the Company, and Takeda has submitted its responsive brief and witness statements. The Company’s reply brief and witness statements are currently scheduled to be filed in November 2011. The hearing on the Company’s claims is currently scheduled to conclude by the end of December 2011. It is not known if the arbitration will remain on schedule or how long thereafter the arbitration proceedings will conclude. The Company has spent and expects to spend significant resources in the dispute with Takeda, and these arbitration proceedings may require the continuing attention of the Company’s senior management.
• The review process for our NDA for lubiprostone for CIC, submitted in September 2010, to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), is proceeding as expected. We have had preliminary meetings with the PMDA. We anticipate receiving approval in early 2012. If successful, NDA approval will be followed by a reimbursement negotiation with the Japanese regulatory authorities.
• Throughout the 2011 third quarter, we continued our discussions with the Swiss reimbursement authorities regarding an appropriate price for lubiprostone for chronic idiopathic constipation or CIC. While those discussions continue, we are moving forward with plans to make AMITIZA available in Switzerland starting in 2012.
• During the 2011 third quarter, we continued to enroll patients into an exploratory clinical study of unoprostone isopropyl on ocular blood flow. We anticipate that the treatment phase of the exploratory clinical study will conclude by the end of 2011. This current exploratory clinical study will enable us to better design the protocol and endpoints for a dose-ranging phase 2 trial in a larger number of dry age-related macular degeneration (dry AMD) patients to determine if unoprostone isopropyl has potential as a treatment for dry AMD.
• In September, we signed a Loan Guarantee and Development Agreement with Numab AG (Numab), a company based in Switzerland. Under the terms of the agreement, Sucampo will provide Numab with up to 5.0 million Swiss francs as collateral for a loan to Numab from a third party. We may name up to four targets against which Numab will use their proprietary technology to discover high-affinity antibodies and to develop these to an Investigational New Drug (IND) ready stage. Numab is eligible for research support payments and discovery success-dependent fees. If a biologic is successfully developed, we may enter into a license agreement with Numab in which Numab will be entitled to clinical development milestone payments and increasing tiered royalties on net sales. We will be responsible for clinical development and will retain all commercial rights to any resulting biologic product.
• We have expanded the Board and senior management. In July 2011, Daniel P. Getman, Ph.D., joined our Board of Directors; in September 2011, Greg Deener joined as Vice President of Marketing, Strategy and Implementation; and in October 2011, Cary J. Claiborne, our Interim CFO since March 2011 joined as CFO. These individuals bring a significant range of industry and professional experience to the company. In September 2011, after five years of leading our R&D, Gayle R. Dolecek, P.D., M.P.H., was appointed Executive Advisor, R&D, reflecting a change to part-time employment. Dr. Dolecek’s responsibilities as Senior Vice President, Research & Development will be shared by Peter Lichtlen, M.D., Ph.D., Senior Medical Officer and Vice President of European Operations, and Taryn R. Joswick, Vice President, Clinical Development. Dr. Dolecek remains a member of our Board of Directors.

Progress towards key milestones for 2011

Sucampo management reiterated today that three of its five key milestones for 2011 have been achieved. They are:

• We completed enrollment into our third phase 3 clinical trial for lubiprostone for OBD. We expect to report top-line results of this trial by year-end 2011;
• We submitted an MAA for lubiprostone for the treatment of CIC in the United Kingdom; and
• We have integrated SAG into the SPI corporate structure, and in September 2011 consolidated our intellectual property in SAG.

The remaining two key milestones for 2011 are:

• Gain approval of a revised label for RESCULA to reflect the current state of scientific understanding on its mechanism of action. In the U.S. the current approved indication is the lowering of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension in patients who are intolerant of or insufficiently responsive to other IOP lowering medications; and
• Make substantial progress towards successfully resolving our dispute with our U.S. partner, Takeda.

Company to Host Conference Call Today

In conjunction with its third quarter and full year financial results, Sucampo will host a conference call today at 5:00 pm Eastern. To participate on the live call, please dial 800-573-4752 (domestic) or 1-617-224-4324 (international), and provide the participant passcode 24832084, five to ten minutes ahead of the start of the call. A replay of the call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-286-8010 (domestic) or 1-617-801-6888 (international), with the passcode 65795051.

Investors interested in accessing the live audio webcast of the teleconference may do so at http://investor.sucampo.com and should log on before the teleconference begins in order to download any software required. The archive of the teleconference will remain available for 30 days.

About unoprostone isopropyl

Sucampo holds development and commercialization rights to unoprostone isopropyl throughout the world except in Japan, Korea, Taiwan and the Peoples Republic of China. Unoprostone isopropyl first received marketing authorization in 1994 and was subsequently approved in over 40 countries, including approval in 2000 by the U.S. FDA.

About lubiprostone

Lubiprostone (trade named AMITIZA) is a local activator of ClC-2 chloride channels in cells lining the small intestine. Lubiprostone increases fluid secretion into the intestinal tract. This increased fluid level softens the stool, facilitating intestinal motility and bowel movements. It is reported that the type 2 chloride channels also play an important role in the restoration of tight junction complexes and in the recovery of barrier function in the body.

About Sucampo Pharmaceuticals, Inc.

Sucampo Pharmaceuticals, Inc., founded in the U.S. in 1996, is an international pharmaceutical company based in Bethesda, Maryland, focused on the discovery, development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Executive Advisor, International Business Development and a member of the Board of Directors. For more information about Sucampo Pharmaceuticals, please visit www.sucampo.com.

Sucampo Forward-Looking Statement

Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words “project,” “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,” “would,” “could,” “will,” ”may” or other similar expressions. Forward-looking statements include statements about the potential utility of UF-021 to treat particular indications and expected data availability dates. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in Sucampo Pharmaceuticals’ filings with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K for the year ended December 31, 2010, and other periodic reports filed with the SEC. Any forward-looking statements in this press release represent Sucampo Pharmaceuticals’ views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, Sucampo Pharmaceuticals specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.

CONTACT:
Sucampo Pharmaceuticals, Inc.
Kate de Santis, 1-240-223-3834
kdesantis@sucampo.com